[go: up one dir, main page]

AR040599A1 - Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad - Google Patents

Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Info

Publication number
AR040599A1
AR040599A1 AR20030102575A ARP030102575A AR040599A1 AR 040599 A1 AR040599 A1 AR 040599A1 AR 20030102575 A AR20030102575 A AR 20030102575A AR P030102575 A ARP030102575 A AR P030102575A AR 040599 A1 AR040599 A1 AR 040599A1
Authority
AR
Argentina
Prior art keywords
macular degeneration
patients
age
protection
related macular
Prior art date
Application number
AR20030102575A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR040599A1 publication Critical patent/AR040599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para prevenir la pérdida de la agudeza visual asociada con la degeneración macular mediante la administración yuxtaescleral de acetato de anecortave o su alcohol. La presente presenta asimismo métodos para mantener la agudeza visual en una persona que sufre de AMD y para inhibir el desarrollo de lesiones asociado con AMD.
AR20030102575A 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad AR040599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05

Publications (1)

Publication Number Publication Date
AR040599A1 true AR040599A1 (es) 2005-04-13

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102575A AR040599A1 (es) 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Country Status (17)

Country Link
US (2) US20060166956A1 (es)
EP (1) EP1539182A4 (es)
JP (1) JP2005535691A (es)
KR (1) KR20050026510A (es)
CN (1) CN1674913A (es)
AR (1) AR040599A1 (es)
AU (1) AU2003281817A1 (es)
BR (1) BR0313546A (es)
CA (1) CA2494211A1 (es)
DE (1) DE03742226T1 (es)
ES (1) ES2244361T1 (es)
MX (1) MXPA05000773A (es)
PL (1) PL375024A1 (es)
RU (1) RU2322239C2 (es)
TW (1) TW200410699A (es)
WO (1) WO2004012742A1 (es)
ZA (1) ZA200500731B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535691A (ja) * 2002-08-05 2005-11-24 アルコン，インコーポレイテッド 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用
WO2004073608A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
EP1663144A1 (en) * 2003-09-23 2006-06-07 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
CN101563051A (zh) * 2006-12-18 2009-10-21 爱尔康研究有限公司 眼用药物递送的装置与方法
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
RU2051651C1 (ru) * 1988-07-07 1996-01-10 Институт химии поверхности АН Украины Основа для глазных капель
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
HK1048427B (en) * 1999-10-21 2005-04-22 Alcon Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
JP2005535691A (ja) * 2002-08-05 2005-11-24 アルコン，インコーポレイテッド 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用
US20070134244A1 (en) * 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
EP1539182A1 (en) 2005-06-15
JP2005535691A (ja) 2005-11-24
EP1539182A4 (en) 2010-01-20
CN1674913A (zh) 2005-09-28
KR20050026510A (ko) 2005-03-15
RU2322239C2 (ru) 2008-04-20
AU2003281817A1 (en) 2004-02-23
BR0313546A (pt) 2005-07-12
DE03742226T1 (de) 2006-03-09
MXPA05000773A (es) 2005-04-19
ZA200500731B (en) 2006-08-30
PL375024A1 (en) 2005-11-14
ES2244361T1 (es) 2005-12-16
TW200410699A (en) 2004-07-01
WO2004012742A1 (en) 2004-02-12
US20040127472A1 (en) 2004-07-01
US20060166956A1 (en) 2006-07-27
RU2005106234A (ru) 2005-08-10
CA2494211A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AR040599A1 (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad
BRPI0608297A2 (pt) composições de lipossomos
CU20090114A7 (es) Formulación liposomal y proceso para la preparación del mismo
BRPI0407485A (pt) utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina
AU2003264282A1 (en) Phenethanolamine derivatives and their use in the treatment of respiratory diseases
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
GT200900049A (es) Derivados de 2-aril-6-fenil-imidazo [1,2-a]piridinas, su preparacion y su aplicacion terapeutica
AR040204A1 (es) Composicion de vacuna meningococica multivalente
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
TW200600117A (en) Preparation for oral administration
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
JP2005535691A5 (es)
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
WO2007128564A3 (en) Use of a compound with rankl activity
PL1781296T3 (pl) Pochodne chinazolinowe i ich zastosowanie w leczeniu nadpłytkowości
AR027937A1 (es) Tratamiento de condiciones alergicas e inflamatorias
AR043252A1 (es) Formulaciones de glucocorticoesteroides para tratar angiogenia ocular patologica
AR055939A1 (es) Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica
AR059126A1 (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada

Legal Events

Date Code Title Description
FB Suspension of granting procedure